ACTRIMS 2021 | REPAIR-MS: 31P-MRS imaging to assess the effects of CNM-Au8 in MS

Robert Glanzman, MD, FAAN, Clene Nanomedicine Inc, Salt Lake City, UT, discusses the interim results from the ongoing Phase II open-label REPAIR-MS trial (NCT03993171), investigating the metabolic effects of CNM-Au8, a gold-based nanocatalyst, in patients with multiple sclerosis (MS). 3 dose levels of CNM-Au8 are under investigation, using high-resolution magnetic resonance spectroscopy (31P-MRS) to assess its activity. When comparing imaging results from patients at baseline and after a minimum of 12 weeks of treatment with CNM-Au8, interim data show bioenergetic improvements in NAD+/NADH ratio and normalization of adenosine triphosphate (ATP) levels, providing evidence that the drug enters the brain and has significant target engagement. These findings indicate that CNM-Au8 has the potential to reverse bioenergetic failure, a key driver in the pathophysiology of MS. This interview took place during the ACTRIMS Forum 2021.